Research progress of sympathetic nervous system in the development of vascular diseases

Home > Archive>Volume 29, Issue 2, 2021 >106-115

Research progress of sympathetic nervous system in the development of vascular diseases
DOI:
                        
                    
CSTR:
                        
                    
Author:
                        CHEN YufeiCHEN Yufei
Department of Physiology and Pathophysiology, Peking University, Beijing 100191, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
KONG WeiKONG Wei
Department of Physiology and Pathophysiology, Peking University, Beijing 100191, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:Department of Physiology and Pathophysiology, Peking University, Beijing 100191, China)
Clc Number:
Fund Project:

Article

Figures

Metrics

Reference [72]

Cited by

Materials

Comments

Reference

[1] Kenney MJ, Ganta CK.Autonomic nervous system and immune system interactions.Compr Physiol, 4,4(3):1177-1200.

[2] De Juan A, Ince LM, Pick R, et al.Artery-associated sympathetic innervation drives rhythmic vascular inflammation of arteries and veins.Circulation, 9,0(13):1100-1114.

[3] De FD, Wattchow D, Costa M, et al.Immunohistochemical characterization of the innervation of human colonic mesenteric and submucosal blood vessels.Neurogastroenterol Motil, 8,0(11):1212-1226.

[4] Kontos A, Lushington K, Martin J, et al.Relationship between vascular resistance and sympathetic nerve fiber density in arterial vessels in children with sleep disordered breathing.J Am Heart Assoc, 7,6(7):e006137.

[5] Makita T, Sucov HM, Gariepy CE, et al.Endothelins are vascular-derived axonal guidance cues for developing sympathetic neurons.Nature, 8,2(7188):759-763.

[6] Brunet I, Gordon E, Han J, et al.Netrin-1 controls sympathetic arterial innervation.J Clin Invest, 4,4(7):3230-3240.

[7] Storkebaum E, Carmeliet P.Paracrine control of vascular innervation in health and disease.Acta Physiol (Oxf), 1,3(1):61-86.

[8] Pardanaud L, Pibouin-Fragner L, Dubrac A, et al.Sympathetic innervation promotes arterial fate by enhancing endothelial ERK activity.Circ Res, 6,9(5):607-620.

[9] Deng Y, Larrivée B, Zhuang ZW, et al.Endothelial RAF1/ERK activation regulates arterial morphogenesis.Blood, 3,1(19):3988-3996.

[10] Simons M, Eichmann A.Molecular controls of arterial morphogenesis.Circ Res, 5,6(10):1712-1724.

[11] Phillips AA, Chan FH, Zheng MM, et al.Neurovascular coupling in humans:Physiology, methodological advances and clinical implications.J Cereb Blood Flow Metab, 6,6(4):647-664.

[12] Burnstock G.Non-synaptic transmission at autonomic neuroeffector junctions.Neurochem Int, 8,2(1/2):14-25.

[13] García-Prieto J, Villena-Gutiérrez R, Gómez M, et al.Neutrophil stunning by metoprolol reduces infarct size.Nat Commun, 7,8:14780.

[14] Wehrwein EA, Orer HS, Barman SM.Overview of the anatomy, physiology, and pharmacology of the autonomic nervous system.Compr Physiol, 6,6(3):1239-1278.

[15] Navar LG.Physiology:hemodynamics, endothelial function, renin-angiotensin-aldosterone system, sympathetic nervous system.J Am Soc Hypertens, 4,8(7):519-524.

[16] Demel SL, Dong H, Swain GM, et al.Antioxidant treatment restores prejunctional regulation of purinergic transmission in mesenteric arteries of deoxycorticosterone acetate-salt hypertensive rats.Neuroscience, 0,8(2):335-345.

[17] Zimmermann H, Zebisch M, Strter N.Cellular function and molecular structure of ecto-nucleotidases.Purinergic Signal, 2,8(3):437-502.

[18] Bodin P, Burnstock G.Purinergic signalling:ATP release.Neurochem Res, 1,6(8/9):959-969.

[19] Brock JA, Dunn WR, Boyd NS, et al.Spontaneous release of large packets of noradrenaline from sympathetic nerve terminals in rat mesenteric arteries in vitro.Br J Pharmacol, 0,1(8):1507-1511.

[20] Hogarth DK, Sandbo N, Taurin S, et al.Dual role of PKA in phenotypic modulation of vascular smooth muscle cells by extracellular ATP.Am J Physiol Cell Physiol, 4,7(2):C449-C456.

[21] Zhu P, Sun W, Zhang C, et al.The role of neuropeptide Y in the pathophysiology of atherosclerotic cardiovascular disease.Int J Cardiol, 6,0:235-241.

[22] Zq J, Zhou YL, Chen X, et al.Different effects of neuropeptide Y on proliferation of vascular smooth muscle cells via regulation of Geminin.Mol Cell Biochem, 7,3(1/2):205-211.

[23] Pons J, Kitlinska J, Jacques D, et al.Interactions of multiple signaling pathways in neuropeptide Y-mediated bimodal vascular smooth muscle cell growth.Can J Physiol Pharmacol, 8,6(7):438-448.

[24] Lee EW, Michalkiewicz M, Kitlinska J, et al.Neuropeptide Y induces ischemic angiogenesis and restores function of ischemic skeletal muscles.J Clin Invest, 3,1(12):1853-1862.

[25] Ju TL, Everhart LM, Abe K, et al.Platelet neuropeptide Y is critical for ischemic revascularization in mice.FASEB J, 3,7(6):2244-2255.

[26] Kitlinska J, Abe K, Kuo L, et al.Differential effects of neuropeptide Y on the growth and vascularization of neural crest-derived tumors.Cancer Res, 5,5(5):1719-1728.

[27] Grassi G, Ram VS.Evidence for a critical role of the sympathetic nervous system in hypertension.J Am Soc Hypertens, 6,0(5):457-466.

[28] Esler M.The sympathetic nervous system through the ages:from Thomas Willis to resistant hypertension.Exp Physiol, 1,6(7):611-622.

[29] Grassi G, Mark A, Esler M.The sympathetic nervous system alterations in human hypertension.Circ Res, 5,6(6):976-990.

[30] Seravalle G, Mancia G, Grassi G.Sympathetic nervous system, sleep, and hypertension.Curr Hypertens Rep, 8,0(9):74.

[31] Biancardi VC, Son SJ, Ahmadi S, et al.Circulating angiotensin Ⅱ gains access to the hypothalamus and brain stem during hypertension via breakdown of the blood-brain barrier.Hypertension, 4,3(3):572-579.

[32] Potapenko ES, Biancardi VC, Zhou Y, et al.Astrocytes modulate a postsynaptic NMDA-GABAA-receptor crosstalk in hypothalamic neurosecretory neurons.J Neurosci, 3,3(2):631-640.

[33] Itani H, Xiao L, Saleh M, et al.CD70 exacerbates blood pressure elevation and renal damage in response to repeated hypertensive stimuli.Circ Res, 6,8(8):1233-1243.

[34] Xiao L, Do Carmo LS, Foss JD, et al.Sympathetic enhancement of memory T-cell homing and hypertension sensitization.Circ Res, 0,6(6):708-721.

[35] Sorota S.The sympathetic nervous system as a target for the treatment of hypertension and cardiometabolic diseases.J Cardiovasc Pharmacol, 4,3(5):466-476.

[36] Myat A, Redwood SR, Qureshi AC, et al.Resistant hypertension.BMJ, 2,5:e7473.

[37] Judd E, Calhoun D.Apparent and true resistant hypertension:definition, prevalence and outcomes.J Hum Hypertens, 4,8(8):463-468.

[38] Johns EJ, Kopp UC, Dibona GF.Neural control of renal function.Compr Physiol, 1,1(2):731-767.

[39] Bramlett HM, Dietrich WD.Progressive damage after brain and spinal cord injury:pathomechanisms and treatment strategies.Prog Brain Res, 7,1:125-141.

[40] Tsai WC, Chan YH, Chinda K, et al.Effects of renal sympathetic denervation on the stellate ganglion and brain stem in dogs.Heart Rhythm, 7,4(2):255-262.

[41] Esler M.Illusions of truths in the symplicity HTN-3 trial:Generic design strengths but neuroscience failings.J Am Soc Hypertens, 4,8(8):593-598.

[42] Bhatt DL, Kandzari DE, O'neill WW, et al.A controlled trial of renal denervation for resistant hypertension.N Engl J Med, 4,0(15):1393-1401.

[43] Townsend RR, Mahfoud F, Kandzari DE, et al.Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF Med):a randomised, sham-controlled, proof-of-concept trial.Lancet, 7,0(1108):2160-2170.

[44] Kandzari DE, B hm M, Mahfoud F, et al.Effect of renal denervation on blood pressure in the presence of antihypertensive drugs:6-month efficacy and safety results from the SPYRAL HTN-ON Med proof-of-concept randomised trial.Lancet, 8,1(1137):2346-2355.

[45] Azizi M, Schmieder RE, Mahfoud F, et al.Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO):a multicentre, international, single-blind, randomised, sham-controlled trial.Lancet, 8,1(1137):2335-2345.

[46] Mulder J, H kfelt T, Knuepfer MM, et al.Renal sensory and sympathetic nerves reinnervate the kidney in a similar time-dependent fashion after renal denervation in rats.Am J Physiol Regul Integr Comp Physiol, 3,4(8):R675-R682.

[47] Paton JF, Sobotka PA, Fudim M, et al.The carotid body as a therapeutic target for the treatment of sympathetically mediated diseases.Hypertension, 3,1(1):5-13.

[48] Pijacka W, Mcbryde FD, Marvar PJ, et al.Carotid sinus denervation ameliorates renovascular hypertension in adult Wistar rats.J Physiol, 6,4(21):6255-6266.

[49] Noller CM, Mendez AJ, Szeto A, et al.Structural remodeling of sympathetic innervation in atherosclerotic blood vessels:role of atherosclerotic disease progression and chronic social stress.Psychosom Med, 7,9(1):59-70.

[50] Robbins CS, Chudnovskiy A, Rauch PJ, et al.Extramedullary hematopoiesis generates Ly-6C(high) monocytes that infiltrate atherosclerotic lesions.Circulation, 2,5(2):364.

[51] 田进伟, 符亚红.动脉粥样硬化易损斑块快速进展机制与临床治疗进展.中国动脉硬化杂志, 9,7(4):277-280.

[52] Al-Sharea A, Lee M, Whillas A, et al.Chronic sympathetic driven hypertension promotes atherosclerosis by enhancing hematopoiesis.Haematologica, 9,4(3):456-467.

[53] Niu X, Pi SL, Baral S, et al.P2Y(12) promotes migration of vascular smooth muscle cells through cofilin dephosphorylation during atherogenesis.Arterioscler Thromb Vasc Biol, 7,7(3):515-524.

[54] Pi S, Mao L, Chen J, et al.The P2RY12 receptor promotes VSMC-derived foam cell formation by inhibiting autophagy in advanced atherosclerosis.Autophagy, 2020, DOI:10.1080/15548627.2020.1741202.

[55] Li L, Najafi AH, Kitlinska JB, et al.Of mice and men:neuropeptide Y and its receptors are associated with atherosclerotic lesion burden and vulnerability.J Cardiovasc Transl Res, 1,4(3):351-362.

[56] Lee EW, Grant DS, Movafagh S, et al.Impaired angiogenesis in neuropeptide Y (NPY)-Y2 receptor knockout mice.Peptides, 3,4(1):99-106.

[57] Wier WG, Zang WJ, Lamont C, et al.Sympathetic neurogenic Ca²＋ signalling in rat arteries:ATP, noradrenaline and neuropeptide Y.Exp Physiol, 9,4(1):31-37.

[58] Li L, J nsson-Rylander AC, Abe K, et al.Chronic stress induces rapid occlusion of angioplasty-injured rat carotid artery by activating neuropeptide Y and its Y1 receptors.Arterioscler Thromb Vasc Biol, 5,5(10):2075-2080.

[59] Kolodgie FD, Burke AP, Nakazawa G, et al.Free cholesterol in atherosclerotic plaques:where does it come from.Curr Opin Lipidol, 7,8(5):500-507.

[60] Virmani R, Kolodgie FD, Burke AP, et al.Atherosclerotic plaque progression and vulnerability to rupture-angiogenesis as a source of intraplaque hemorrhage.Arterioscler Thromb Vasc Biol, 5,5(10):2054-2061.

[61] Choi B, Shin MK, Kim EY, et al.Elevated neuropeptide Y in endothelial dysfunction promotes macrophage infiltration and smooth muscle foam cell formation.Front Immunol, 9,0:1701.

[62] Ciarka A, Doan V, Velez-Roa S, et al.Prognostic significance of sympathetic nervous system activation in pulmonary arterial hypertension.Am J Respir Crit Care Med, 0,1(11):1269-1275.

[63] Maron B, Leopold JA.Emerging concepts in the molecular basis of pulmonary arterial hypertension:part II:neurohormonal signaling contributes to the pulmonary vascular and right ventricular pathophenotype of pulmonary arterial hypertension.Circulation, 5,1(23):2079-2091.

[64] Crnkovic S, Egemnazarov B, Jain P, et al.NPY/Y1 receptor-mediated vasoconstrictory and proliferative effects in pulmonary hypertension.Br J Pharmacol, 4,1(16):3895-3907.

[65] Luo Q, Wang X, Liu R, et al.Alpha1A-adrenoceptor is involved in norepinephrine-induced proliferation of pulmonary artery smooth muscle cells via CaMKII signaling.J Cell Biochem, 9,0(6):9345-9355.

[66] Ishikawa M, Sato N, Asai K, et al.Effects of a pure alpha/beta-adrenergic receptor blocker on monocrotaline-induced pulmonary arterial hypertension with right ventricular hypertrophy in rats.Circ J, 9,3(12):2337-2341.

[67] Bogaard HJ, Natarajan R, Mizuno S, et al.Adrenergic receptor blockade reverses right heart remodeling and dysfunction in pulmonary hypertensive rats.Am J Respir Crit Care Med, 0,2(5):652-660.

[68] Okumura K, Kato H, Honjo O, et al.Carvedilol improves biventricular fibrosis and function in experimental pulmonary hypertension.J Mol Med (Berl), 5,3(6):663-674.

[69] Zhang S, Zhao Q, Jiang X, et al.Beneficial effects of renal denervation on pulmonary vascular remodeling in experimental pulmonary artery hypertension.Zhonghua Yi Xue Za Zhi, 5,5(14):1108-1112.

[70] Liu Q, Song JY, Lu DS, et al.Effects of renal denervation on monocrotaline induced pulmonary remodeling.Oncotarget, 7,8(29):46846-46855.

[71] Na S, Kim OS, Ryoo S, et al.Cervical ganglion block attenuates the progression of pulmonary hypertension via nitric oxide and arginase pathways.Hypertension, 4,3(2):309-315.

[72] Huang Y, Liu YW, Pan HZ, et al.Transthoracic pulmonary artery denervation for pulmonary arterial hypertension.Arterioscler Thromb Vasc Biol, 9,9(4):704-718.

Get Citation

CHEN Yufei, KONG Wei. Research progress of sympathetic nervous system in the development of vascular diseases[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2021,29(2):106-115.

Copy

Article Metrics

Abstract:681
PDF: 1819
HTML: 0
Cited by: 0

History

Received:October 26,2020
Revised:November 23,2020
Adopted:
Online: February 03,2021
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code